Gassó, P. http://orcid.org/0000-0001-6930-3454
Rodríguez, N. http://orcid.org/0000-0002-9618-9383
Martínez-Pinteño, A.
Mezquida, G.
Ribeiro, M.
González-Peñas, J. http://orcid.org/0000-0002-3850-3012
Zorrilla, I.
Martínez-Sadurni, L.
Rodriguez-Jimenez, R.
Corripio, I.
Sarró, S. http://orcid.org/0000-0003-1835-2189
Ibáñez, A. http://orcid.org/0000-0003-2751-0150
Usall, J.
Lobo, A. http://orcid.org/0000-0002-9098-655X
Moren, C.
Cuesta, M. J.
Parellada, M.
González-Pinto, A.
Berrocoso, E.
Bernardo, M. http://orcid.org/0000-0001-8748-6717
Mas, S. http://orcid.org/0000-0003-3336-6298
Bioque, M.
Amoretti, S.
Andreu-Bernabeu, A.
Gurriarán, X.
Alonso-Solís, A.
Grasa, E.
López, P.
Garcia, E.
Bergé, D.
Trabsa, A.
Sànchez-Pastor, L.
Jiménez-Rodríguez, O.
Pomarol-Clotet, E.
Feria-Raposo, I.
Butjosa, A.
Pardo, M.
Moreno-Izco, L.
Sánchez-Torres, A. M.
Saiz-Ruiz, J.
León-Quismondo, L.
Nacher, J.
Contreras, F.
De-la-Cámara, C.
Gutiérrez, M.
Sáiz, P. A.
,
Article History
Received: 3 May 2021
Revised: 22 September 2021
Accepted: 30 September 2021
First Online: 19 October 2021
Competing interests
: A. Ibáñez has received research support from or served as speaker or advisor for JanssenCilag, Lundbeck, and Otsuka. J. Saiz-Ruiz has been as speaker for and on the advisory boards of Adamed, Lundbeck, Servier, Medtronic, Casen Recordati, Neurofarmagen, Otsuka, Indivior, Lilly, Schwabe, Janssen, and Pfizer, outside the submitted work. M. Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi, and Takeda. M. Bioque has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of has received honoraria from talks and/or consultancy of Adamed, Angelini, Ferrer, Janssen-Cilag, Lundbeck, Neuraxpharm, Otsuka, Pfizer, and Sanofi, and grants from Spanish Ministry of Health, Instituto de Salud Carlos III. P. A. Saiz has been a consultant to and/or has received honoraria or grants from Adamed, CIBERSAM, European Comission, Government of the Principality of Asturias, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Plan Nacional Sobre Drogas, and Servier. R. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; S2017/BMD-3740), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda, Exeltis, Casen Recordati, and Angelini.